Virax Biolabs Group (Virax Biolabs Group) Cash-to-Debt : 28.07 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Virax Biolabs Group's cash to debt ratio for the quarter that ended in Sep. 2023 was 28.07.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Virax Biolabs Group could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Virax Biolabs Group's Cash-to-Debt or its related term are showing as below:

VRAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12 Med: 64.06 Max: No Debt
Current: 28.07

During the past 4 years, Virax Biolabs Group's highest Cash to Debt Ratio was No Debt. The lowest was 0.12. And the median was 64.06.

VRAX's Cash-to-Debt is ranked better than
67.6% of 1537 companies
in the Biotechnology industry
Industry Median: 6.49 vs VRAX: 28.07

Virax Biolabs Group Cash-to-Debt Historical Data

The historical data trend for Virax Biolabs Group's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Virax Biolabs Group Cash-to-Debt Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

No Debt

64.06

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial			0.12	No Debt	11.72	64.06	28.07

Competitive Comparison of Virax Biolabs Group's Cash-to-Debt

For the Biotechnology subindustry, Virax Biolabs Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Cash-to-Debt falls into.

Virax Biolabs Group Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Virax Biolabs Group's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.353	/	(0.146	+	0)
	=	64.06

Virax Biolabs Group's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.108	/	(0.05	+	0.132)
	=	28.07

Virax Biolabs Group (NAS:VRAX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Virax Biolabs Group Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.